The First Autopsy Case of Fatal Acute Cardiac Failure after Administration of Carfilzomib in a Patient with Multiple Myeloma
Carfilzomib (CFZ) improves progression-free survival for patients with relapsed or refractory multiple myeloma (MM) but has shown higher frequency of cardiovascular adverse events (CVAEs) than other proteasome inhibitors. We report the first autopsy case of acute death from cardiac failure shortly a...
Saved in:
Main Authors: | Teruhito Takakuwa, Ippei Otomaru, Taku Araki, Akiko Miura, Yotaro Fujitani, Yasuhide Mochizuki, Yoshimi Miyagi, Hideto Senzaki, Ryosuke Yamamura |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2019/1816287 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
by: Giuseppe Mele, et al.
Published: (2018-01-01) -
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01) -
Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma
by: Deborah Osafehinti, et al.
Published: (2019-01-01) -
Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profiling
by: Conagh Kelly, et al.
Published: (2025-02-01) -
Clinical autopsy and informed consent.
by: Javier Martínez Navarro
Published: (2018-04-01)